sanofi-aventis licenses Oxford BioTherapeutics’ antibody program for treatment of solid cancers
OXFORD, U.K.—Oxford BioTherapeutics (OBT) recently announced that sanofi-aventis has acquired an exclusive worldwide license to one of its internal preclinical antibody programs. sanofi-aventis intends to use the licensed antibody, which is directed against a novel, proprietary target identified by OBT, to develop, manufacture and commercialize antibody drug conjugate (ADC) products for the treatment of cancer. ADC products comprise toxins attached to antibodies, which form effective therapeutic products that attack tumor cells in a highly targeted manner. Under the terms of the agreement, sanofi-aventis agreed to pay OBT an undisclosed upfront cash payment. OBT is also eligible to receive development and regulatory milestone payments, royalties on worldwide products sales and additional performance milestones.
"This is the most advanced antibody licensing deal that OBT has signed to date," says Christian Rohlff, OBT's CEO. "Given their expertise and experience in cancer drug development, I am very pleased that a program from our broad preclinical pipeline will be developed by sanofi-aventis."